IDEXX (IDXX) director granted stock options and deferred stock units

Rhea-AI Filing Summary

IDEXX Laboratories director Karen Peacock reported equity compensation awards. She received 234 deferred stock units and a non-qualified stock option covering 525 shares of common stock, both recorded as grants, not open-market purchases.

The stock option has an exercise price of $533.92 per share and expires in May 2036. Both the option and the deferred stock units vest in a single installment on the earlier of one year from grant or the 2027 annual meeting of shareholders. The deferred stock units are payable in common stock after her resignation from the board.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Peacock Karen

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right-to-buy)	525	$0.00	--
Grant/Award	Deferred Stock Unit	234	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (right-to-buy) — 525 shares (Direct, null); Deferred Stock Unit — 234 shares (Direct, null)

Footnotes (1)

1. Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier. Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

Key Figures

Deferred stock units granted: 234 units Stock option shares granted: 525 shares Option exercise price: $533.92 per share +3 more

6 metrics

Deferred stock units granted 234 units Director equity award

Stock option shares granted 525 shares Non-qualified stock option award

Option exercise price $533.92 per share Non-qualified stock option strike price

Option expiration May 11, 2036 Non-qualified stock option term end

Deferred units post-transaction 234 units Total deferred stock units following grant

Options post-transaction 525 options Total option units from this grant

Key Terms

Deferred Stock Unit, Non-Qualified Stock Option (right-to-buy), exercise price, annual meeting of shareholders

4 terms

Deferred Stock Unit financial

"Each deferred stock unit represents a contingent right to receive one share of Issuer common stock."

A deferred stock unit (DSU) is a promise from a company to give an employee or director the value of a share at a future date, paid in actual shares or cash when certain conditions are met (such as retirement or a set date). Think of it like a gift card that converts to company stock later; it aligns pay with long‑term performance and can affect future share count, compensation expense and potential cash needs, so investors watch DSUs for their impact on dilution and company finances.

Non-Qualified Stock Option (right-to-buy) financial

"Grant of option to buy shares of Issuer common stock that vest in one installment."

exercise price financial

"Non-Qualified Stock Option (right-to-buy) with a conversion or exercise price of 533.9200."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of shareholders financial

"Vests in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders."

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peacock Karen

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK MAINE 04092

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy)	$533.92	05/12/2026		A		525		(1)	05/11/2036	Common Stock	525	$0	525	D
Deferred Stock Unit	(2)	05/12/2026		A		234		(2)	(2)	Common Stock	234	$0	234	D

Explanation of Responses:

1. Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.

2. Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Karen Peacock	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did IDEXX (IDXX) director Karen Peacock report?

Karen Peacock reported two equity compensation grants: 234 deferred stock units and a non-qualified stock option for 525 shares. Both are awards from IDEXX Laboratories, not open-market purchases or sales, and are tied to her role as a director.

How many IDEXX (IDXX) deferred stock units did Karen Peacock receive?

Karen Peacock received 234 deferred stock units. Each unit represents the right to receive one share of IDEXX common stock. These units vest in one installment and are generally payable in stock after she resigns from the board of directors.

What are the key terms of Karen Peacock’s IDEXX (IDXX) stock option grant?

She was granted a non-qualified stock option for 525 shares with an exercise price of $533.92 per share and an expiration date in May 2036. The option vests in a single installment based on time or the 2027 annual meeting.

When do Karen Peacock’s IDEXX (IDXX) equity awards vest?

Both the stock option and deferred stock units vest in one installment on the earlier of one year from the grant date or the IDEXX 2027 annual meeting of shareholders. Vesting determines when she earns the right to the underlying shares.

Are Karen Peacock’s IDEXX (IDXX) Form 4 transactions open-market trades?

No. The Form 4 shows grant or award acquisitions of a stock option and deferred stock units. These are compensation-related equity awards from IDEXX Laboratories, not open-market purchases or sales initiated by the director.